DOCSLIB.ORG

Lipid-Lowering Drugs and Risk of New- Onset Diabetes: a Cohort Study Using Japanese Healthcare Data Linked to Clinical Data for Health Screening

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lipid-Lowering Drugs and Risk of New- Onset Diabetes: a Cohort Study Using Japanese Healthcare Data Linked to Clinical Data for Health Screening Open Access Research BMJ Open: first published as 10.1136/bmjopen-2017-015935 on 30 June 2017. Downloaded from Lipid-lowering drugs and risk of new- onset diabetes: a cohort study using Japanese healthcare data linked to clinical data for health screening Nobuhiro Ooba,1 Soko Setoguchi,2 Tsugumichi Sato,3 Kiyoshi Kubota4 To cite: Ooba N, Setoguchi S, ABSTRACT Strengths and limitations of this study Sato T, et al. Lipid-lowering Objective To investigate whether lipid-lowering drugs drugs and risk of new-onset are associated with new-onset diabetes after adjusting for diabetes: a cohort study ► This was not a randomised controlled trial but a baseline clinical risk factors for diabetes. using Japanese healthcare retrospective cohort study using health insurance data linked to clinical data for Design A retrospective cohort study. claims data linked to clinical and laboratory data health screening. BMJ Open Setting Japanese employees of large corporations and for annual health screenings and subject to the 2017;7:e015935. doi:10.1136/ their dependents using health insurance claims data confounding bias even if the bias was adjusted as bmjopen-2017-015935 linked to clinical and laboratory data for annual health much as possible. screenings. Prepublication history for ► Our study population included those who worked in ► Participants All persons aged 20 to 74 years with this paper is available online. relatively large corporations and their relatives, aged To view these files please visit dyslipidaemia between 1 January 2005 and 31 March between 20 and 74 years, which means our findings the journal online (http:// dx. doi. 2011. We defined the index date as the first date when might not be readily generalised to those working in org/ 10. 1136/ bmjopen- 2017- the person met the criteria for dyslipidaemia. Persons small corporations or self-employed individuals and 015935). were excluded if they had lipid-lowering drugs, or had old people aged ≥75 years. a diagnosis, a treatment or a laboratory test result The diagnosis code for diabetes was not validated Received 11 January 2017 ► (haemoglobin A1c ≥6.5% or fasting blood glucose in our database, and therefore the outcome Revised 13 May 2017 ≥126 mg/dL) indicating diabetes during the 6-month Accepted 24 May 2017 in sensitivity analyses was defined using an period before the index date. antidiabetic drug with or without the diagnosis code Main outcome measures New-onset diabetes. for diabetes. http://bmjopen.bmj.com/ Results We identified 68 620 persons with dyslipidaemia. ► Although the information on some of potential During the mean follow-up period of 1.96 years, 3674 confounders such as smoking, alcohol consumption persons started treatment with a lipid-lowering drug: and physical exercise was not available, we could 979 with a low potency statin, 2208 with a high potency adjust for several important risk factors of diabetes statin and 487 with a fibrate. Of 3674 new users of a such as HbA1c and fasting blood glucose essential lipid-lowering drug, 3621 had a period of non-use of any in diagnosis of diabetes, as well as body mass index, lipid-lowering drugs before starting a lipid-lowering drug. blood pressure, uric acid, low-density lipoprotein Among statin users, the incidence rate of new-onset cholesterol cholesterol, high-density lipoprotein diabetes was 124.6 per 1000 person-years compared with cholesterol cholesterol, triglyceride and urinary on September 25, 2021 by guest. Protected copyright. 22.6 per 1000 person-years in non-users. After adjusting glucose. for confounding factors including clinical data in health ► Our study suggested that the use of statins was 1Department of Clinical screening using Cox proportional hazards models, the HR associated with an increased risk of new-onset Pharmacy, Nihon University was 1.91 (95% CI 1.38 to 2.64) for low potency statins and diabetes, compared with the period of non-use, School of Pharmacy, Funabashi, 2.61 (2.11 to 3.23) for high potency statins. despite adjusting for risk factors for diabetes (eg, Chiba, Japan Conclusion The use of statins was associated with a 1.9- HbA1c and body mass index) obtained in the annual 2Institute for Health, Health Care fold to 2.6-fold increase in the risk of new-onset diabetes health screening. Policy and Aging Research, in a Japanese population of working age, despite adjusting ► We also found that the risk of new-onset diabetes Rutgers University and Rutgers for clinical risk factors for diabetes. Robert Wood Johnson Medical using high potency statins (atorvastatin, rosuvastatin School, New Brunswick, New and pitavastatin) was higher than that of low potency statins (fluvastatin, pravastatin and simvastatin). Jersey, USA INTRODUCTION 3Department of Pharmacy, Tokyo University of Science, Yamazaki, Hyperlipidaemia is an established risk factor Noda, Chiba, Japan for cardiovascular diseases. In Japan, the 4NPO Drug Safety Research Unit estimated number of patients with hyper- general, although rare adverse reactions Japan, Tokyo, Japan lipidaemia was approximately 1.9 million at such as liver dysfunction and rhabdomyolysis 1 3 Correspondence to 2011. Statins are widely used for primary can occur. According to recent studies, the Dr Kiyoshi Kubota; kubotape- and secondary prevention of cardiovascular use of statins is associated with an increased tky@ umin. net diseases2 and have a good safety profile in risk of new-onset diabetes.4–6 As with Ooba N, et al. BMJ Open 2017;7:e015935. doi:10.1136/bmjopen-2017-015935 1 Open Access BMJ Open: first published as 10.1136/bmjopen-2017-015935 on 30 June 2017. Downloaded from hyperlipidaemia, diabetes is an established risk factor the heath guidance outcome. The data for 215 307 bene- for cardiovascular diseases,7 and therefore the possible ficiaries aged between 20 and 74 years in the study period increased risk of new-onset diabetes by the drugs used (1 January 2005 to 31 March 2011) were collected and to treat hyperlipidaemia may attenuate the effect of maintained by Japan Medical Data Centre Co.13 Infor- reducing the risk of cardiovascular diseases. mation on healthcare utilisation, such as outpatient visits Meta-analyses of randomised trials report that the use and hospitalisation, drugs, medical procedures and diag- of statins was associated with a modestly increased risk noses, was available from the claims data. With respect to of diabetes (overall OR=1.09, 95% CI: 1.02 to 1.17) and drug information14 within the claims, more than 20 000 the OR for individual statins ranged from 0.98 to 1.18.4 local codes are used to specify the trade name and dosage However, randomised trials may not accurately represent form for all approved drugs. Codes for medical proce- actual practice or patients. The results from observa- dures include order of laboratory tests such as HbA1c, tional studies are not consistent. A study using data from triglyceride (TG), total cholesterol, low-density lipopro- the women’s health initiative found that high potency tein (LDL) cholesterol and high-density lipoprotein statins (HR 1.45) and low potency statins (HR 1.48) were (HDL) cholesterol. The 10th revision of the International similarly associated with the increased risk of diabetes.5 Classification of Diseases was used for diagnoses. The On the other hand, in a study using the administrative enrolment data contained the dates of enrolment and healthcare database of Ontario,6 high potency statins had disenrollment. Annual health screening is mandatory for a slightly higher risk than that of low/moderate potency employees irrespective of whether they have already had statins (HR 1.22 vs 0.97/1.11). The association between cardiovascular and other diseases under the Industrial fibrates and new-onset diabetes indicated inconsistent Safety and Health Act, and optional for their depen- results in a small number of previous studies.8 9 dents.15 The health screening data contained values of One potential reason for the inconsistency in assessing BMI, systolic and diastolic blood pressure, total choles- the magnitude of diabetes risk, arising from previous terol, LDL cholesterol, HDL cholesterol, TG, HbA1c, observational studies, may be due to the unavailability FBG, serum creatinine (SCre), uric acid (UA), urinary of information on the important confounders, such as glucose and urinary protein. cholesterol level, blood pressure, body mass index (BMI), haemoglobin A1c (HbA1c) and fasting blood glucose Study cohort (FBG). The inability to control for these factors that poten- We identified 94 630 subjects with or without prior tially introduce confounding by indication or severity cardiovascular diseases who had either total cholesterol may have created an association between the use of a ≥220 mg/dL, LDL cholesterol ≥140 mg/dL, HDL choles- statin with new-onset diabetes variably targeting different terol <40 mg/dL or TG ≥150 mg/dL measured at the study populations in previous studies. It is also unclear annual health screening period between 1 January 2005 http://bmjopen.bmj.com/ whether the risk of new-onset diabetes is specific to statins and 31 March 2011 (figure 1).16 17 We defined the index or common to lipid-lowering drugs (LLDs) including date as the first date when one of these criteria was met fibrates. In addition, there have been few reports on the and the baseline period as the period when the data on association between statins and the incidence of diabetes claims and health screening were available, after the date in the Asian population.10 11 We conducted a cohort study of enrolment but before the index date. Subjects were using claims data linked to the health screening data excluded if they had a baseline period of <6 months, had including blood pressure, BMI, HbA1c, FBG and other a diagnosis of diabetes, had used an antidiabetic drug laboratory test results to assess the association between or had a test result indicating diabetes (HbA1c≥6.5% or on September 25, 2021 by guest.
Load more

Recommended publications
  • Lipid Lowering Agents, Cognitive Decline, and Dementia: the Three-City Study
    Lipid lowering agents, cognitive decline, and dementia: the three-city study. Marie-Laure Ancelin, Isabelle Carrière, Pascale Barberger-Gateau, Sophie Auriacombe, Olivier Rouaud, Spiros Fourlanos, Claudine Berr, Anne-Marie Dupuy, Karen Ritchie To cite this version: Marie-Laure Ancelin, Isabelle Carrière, Pascale Barberger-Gateau, Sophie Auriacombe, Olivier Rouaud, et al.. Lipid lowering agents, cognitive decline, and dementia: the three-city study.: Lipid Lowering Agents and Cognitive Decline. Journal of Alzheimer’s Disease, IOS Press, 2012, 30 (3), pp.629-37. 10.3233/JAD-2012-120064. inserm-00707350 HAL Id: inserm-00707350 https://www.hal.inserm.fr/inserm-00707350 Submitted on 12 Jun 2012 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Lipid lowering agents, cognitive decline, and dementia: the three-city study Marie-Laure Ancelin 1 * , Isabelle Carrière 1 , Pascale Barberger-Gateau 2 , Sophie Auriacombe 2 , Olivier Rouaud 3 , Spiros Fourlanos 4 , Claudine Berr 1 , Anne-Marie Dupuy 1 5 , Karen Ritchie 1 6 1 Neuropsychiatrie : Recherche Epidémiologique
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • The Effects of Statin and Fibrate Drugs on Cholesterol Metabolism And
    The effects of statin and fibrate drugs on cholesterol metabolism and steroid production in two fish species. By Aziz Al-Habsi Thesis submitted to the Faculty of Graduate and Postdoctoral Studies University of Ottawa In partial fulfillment of the requirements for the PhD degree in the Ottawa-Carleton Institute of Biology Thèse soumise à la Faculté des Études Supérieurs et Postdoctorales Université d’Ottawa En vue de la réalisation partielle du doctorat à L’Institut de Biologie Ottawa-Carleton ©Aziz Al-Habsi, Ottawa, Canada, 2014 This thesis is dedicated to my wife and children who have always stood by me and dealt with all my absence from many family occasions with a smile. ii Acknowledgments Completing a PhD is truly a marathon event, and I would not have able to complete this journey without the aid and support of countless people over the past seven years. First and foremost I would like to gratefully and sincerely thank my supervisor Dr. Thomas W. Moon for his guidance, understanding, friendship, and most importantly, his patience during my graduate studies at University of Ottawa. His mentorship was paramount in providing a well-rounded experience consistent my long-term career goals. He encouraged me not only to be a biologist but also be an instructor and independent thinker. I am not sure many graduate students are given the opportunity to develop their own individuality and self- sufficiency by being allowed to work with such independence. For everything you’ve done for me, Dr. Moon, I thank you. I would like to extend my thanks the Department of Biology at University of Ottawa, especially those members of my doctoral committee for their input, valuable discussions and accessibility.
    [Show full text]
  • Lipid Management Protocol
    Lipid Management Protocol RISK GOALS FOR CLINICAL MANAGEMENT LIFESTYLE CATEGORIES THERAPY INTERVENTIONS MODIFICATIONS Evaluate for ten (10) Initial Assessment: Recommendations years CVD risk. • Assess fasting lipid panel (FLP) for • Encourage weight loss/ baseline. LDL is primary focus. management. Risk Factors include: • Smoking • If LDL-C cannot be calculated due to • Promote increased daily • Hypertension elevated triglyceride level, order LDL-C physical activity. • Dyslipidemia direct measurement or calculate Non-HDL • Low HDL (Exclusive cholesterol. • Referral for medical of LDL) nutrition therapy (covered • Diabetes • FLP within 24 hours of hospitalization for by most payers) • Obesity an acute event and recheck FLP in 12 • Family History weeks. - Limit diet to <7% • Age saturated fats and <200 Men ≥ 45 • Periodically recheck FLP thereafter until mg/dL of cholesterol Women ≥ 55 goal values are met. from total calories. Metabolic Syndrome* • Consider fasting glucose on all initial - Increased consumption protocols and prn. of monounsaturated fatty acids (olive/ peanut/ canola oils, RISK CATEGORIES nuts/peanut butter, avocado, olives). 0-1 Low Risk (<10% in 10 yrs) LDL<160 and • If LDL is ≥ 130 mg/dL (Baseline or on - Include 6 oz. of fish/wk, Non-HDL<190 treatment) start or intensify lipid lowering specifying tuna, herring Ideal <130 therapy to reach goal (statin preferred). or salmon or 1000 mg and Non- (If patient is hospitalized, start statin.) fish oil per day. HDL<160 2 + Moderate Risk • If LDL 100-129 mg/dL (Baseline or on - Encourage increased (10 - 20% in 10 yrs) treatment): consumption of complex LDL<130 and - Start lipid lowering therapy (statin carbohydrates. Non-HDL<160 preferred).
    [Show full text]
  • 1 Lipid Lowering Agents, Cognitive Decline, and Dementia
    Lipid Lowering Agents, Cognitive Decline, and Dementia: The Three-City Study Marie-Laure Ancelin, PhD.a,b,§,*, Isabelle Carrière, PhD.a,b,§, Pascale Barberger-Gateau PhD.c, Sophie Auriacombe, MDc, Olivier Rouaud, MDd, Spiros Fourlanos, MD, PhD.e, Claudine Berr, PhD.a,b, Anne-Marie Dupuy, PhD.a,b,f, Karen Ritchie, PhD.a,b,g Running title: Lipid Lowering Agents and Cognitive Decline a Inserm, U1061, Montpellier, F-34093 France b Université Montpellier 1, Montpellier, France c Inserm, U897, Bordeaux, F-33076 France d Centre Mémoire Ressources et Recherche, Centre Hospitalier Universitaire, Dijon, France e Department of Diabetes & Endocrinology, Royal Melbourne Hospital, Melbourne, Australia f CHU Montpellier, Laboratoire de Biochimie, Hopital Lapeyronie, Montpellier, France g Faculty of Medicine, Imperial College, London, W12 0NN, U.K. *Corresponding author: Inserm U1061, Hopital La Colombiere, 39, avenue C. Flahault, BP 34493, 34093 Montpellier Cedex 5, France Tel: +33 499 614 562; Fax: +33 499 614 579; E-mail address: [email protected] § Joint first authors Declaration of interest: No conflict of interest. Paper length: 2863 words Title character count: 67 Abstract: 231 words 3 Tables 1 Abstract The aim of this prospective cohort study was to evaluate the effects of lipid lowering agent (LLA) intake on cognitive function in 6830 community-dwelling elderly persons. Cognitive performance (global cognitive functioning, visual memory, verbal fluency, psychomotor speed and executive function), clinical diagnosis of dementia, and fibrate and statin use, were evaluated at baseline, and 2, 4, and 7 year follow-up. Multivariate Cox models were stratified by gender and adjusted for sociodemographic characteristics, mental and physical health including vascular risk factors, and genetic vulnerability (apolipoprotein E and cholesteryl ester transfer protein).
    [Show full text]
  • UMHS Guideline Screening and Management of Lipids
    Guidelines for Clinical Care Quality Department Ambulatory Lipid Therapy Screening and Management of Lipids Guideline Team Team Leader Patient population: Adults age 20–79 years without familial or severe dyslipidemias or chronic Audrey L. Fan, MD kidney disease (CKD). (In patients with CKD, see UMHS Management of Chronic Kidney Disease.) General Medicine Objective: Primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) Team Members through lipid screening, determining treatment benefit and risk, and providing appropriate treatment. Jill N. Fenske, MD Family Medicine Key Points R. Van Harrison, PhD Obtain a screening / baseline lipid profile Medical Education Patients. Men age ≥ 35 and women age ≥ 45 years. Also men age 20–35 and women age 20–45 who are Melvyn Rubenfire, MD at increased risk for ASCVD [IC*]. Can also consider a screening or baseline lipid profile in adults Cardiology age ≥ 20 when assessing traditional ASCVD risk factors (age, sex, total cholesterol, HDL-C, systolic Marie A. Marcelino, BP, use of antihypertensive therapy, diabetes, and smoking) [IIC*]. PharmD Fasting/non-fasting. Screening lipid profile can be obtained fasting or non-fasting. Pharmacy Services Prior to considering drug treatment for dyslipidemias at any age exclude secondary causes (Table 1). Consultant, 2020 revision Assess ASCVD risk. Does the patient have any of the following risk factors? Trisha D. Wells, PharmD Clinical ASCVD. This includes stroke/TIA, carotid and peripheral arterial disease, and clinical evidence Pharmacy Services of coronary heart disease. Initial Release LDL-C ≥ 190 mg/dL and age ≥ 20, not caused by drugs or an underlying medical condition (Table 1). May 2000 Diabetes mellitus type 1 or 2, and age 40–75 years, with LDL-C 70–189 mg/dL.
    [Show full text]
  • Metabolic Regulation by Lipid Activated Receptors by Maxwell A
    Metabolic Regulation by Lipid Activated Receptors By Maxwell A Ruby A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy In Molecular & Biochemical Nutrition In the Graduate Division Of the University of California, Berkeley Committee in charge: Professor Marc K. Hellerstein, Chair Professor Ronald M. Krauss Professor George A. Brooks Professor Andreas Stahl Fall 2010 Abstract Metabolic Regulation by Lipid Activated Receptors By Maxwell Alexander Ruby Doctor of Philosophy in Molecular & Biochemical Nutrition University of California, Berkeley Professor Marc K. Hellerstein, Chair Obesity and related metabolic disorders have reached epidemic levels with dire public health consequences. Efforts to stem the tide focus on behavioral and pharmacological interventions. Several hypolipidemic pharmaceutical agents target endogenous lipid receptors, including the peroxisomal proliferator activated receptor α (PPAR α) and cannabinoid receptor 1 (CB1). To further the understanding of these clinically relevant receptors, we elucidated the biochemical basis of PPAR α activation by lipoprotein lipolysis products and the metabolic and transcriptional responses to elevated endocannabinoid signaling. PPAR α is activated by fatty acids and their derivatives in vitro. While several specific pathways have been implicated in the generation of PPAR α ligands, we focused on lipoprotein lipase mediated lipolysis of triglyceride rich lipoproteins. Fatty acids activated PPAR α similarly to VLDL lipolytic products. Unbound fatty acid concentration determined the extent of PPAR α activation. Lipolysis of VLDL, but not physiological unbound fatty acid concentrations, created the fatty acid uptake necessary to stimulate PPAR α. Consistent with a role for vascular lipases in the activation of PPAR α, administration of a lipase inhibitor (p-407) prevented PPAR α dependent induction of target genes in fasted mice.
    [Show full text]
  • Global Hypercoagulability in Patients with Schizophrenia Receiving Long-Term Antipsychotic Therapy
    Schizophrenia Research 162 (2015) 175–182 Contents lists available at ScienceDirect Schizophrenia Research journal homepage: www.elsevier.com/locate/schres Global hypercoagulability in patients with schizophrenia receiving long-term antipsychotic therapy Vincent Chow a,b,c,CarolineReddela,b,c, Gabrielle Pennings a,b,c, Elizabeth Scott d,TundraPasqualone, Austin C.C. Ng b,c,ThomasYeohb, Jennifer Curnow a,c,f, Leonard Kritharides a,b,c,⁎ a ANZAC Research Institute, Sydney, Australia b Department of Cardiology, Concord Repatriation General Hospital, Sydney Local Health District, Sydney, Australia c University of Sydney, Australia d Brain & Mind Research Institute, University of Sydney, Australia e Department of Psychiatry, Croydon Health Centre, Sydney, Australia f Department of Haematology, Concord Repatriation General Hospital, Sydney Local Health District, Sydney, Australia article info abstract Article history: Background: Patients with schizophrenia are at increased risk of venous thromboembolism. The mechanisms Received 21 January 2014 underlying this association are poorly understood. Received in revised form 4 December 2014 Aims: We investigated whether there is a global hypercoagulable state in patients with schizophrenia utilising the Accepted 6 December 2014 overall haemostatic potential (OHP) assay which assesses overall coagulation potential (OCP), haemostatic Available online 27 January 2015 potential (OHP) and fibrinolytic potential (OFP). Method: Citrated plasma was collected for OHP assays from patients with schizophrenia on long-term antipsy- Keywords: chotic treatment and compared with healthy age- and sex-matched controls. Time courses of fibrin formation Schizophrenia Blood coagulation test and degradation were measured by spectrophotometry (absorption of 405 nm) after the addition of tissue factor Coagulation and tissue plasminogen activator to plasma.
    [Show full text]
  • Repression of Glucocorticoid-Stimulated Angiopoietin-Like 4 Gene Transcription by Insulin
    Repression of glucocorticoid-stimulated angiopoietin-like 4 gene transcription by insulin Taiyi Kuo , * ,† Tzu-Chieh Chen , † Stephanie Yan , † Fritz Foo , † Cecilia Ching , † Allison McQueen , † and Jen-Chywan Wang 1, * ,† Endocrinology Graduate Program* and Department of Nutritional Sciences & Toxicology, † University of California, Berkeley , Berkeley, CA 94720-3104 Abstract Angiopoietin-like 4 (Angptl4) is a glucocorticoid re- into monoacylglycerol and FFAs, which can then be taken Downloaded from ceptor (GR) primary target gene in hepatocytes and adipo- up into the cells. Angptl4 can also induce lipolysis in adi- cytes. It encodes a secreted protein that inhibits extracellular pocytes ( 1–4 ). For adipocytes, the net metabolic effect of LPL and promotes adipocyte lipolysis. In Angptl4 null mice, Angptl4 is to mobilize lipids to plasma. The importance of glucocorticoid-induced adipocyte lipolysis and hepatic ste- Angptl4 in the regulation of lipid homeostasis is supported atosis are compromised. Markedly, insulin suppressed glucocorticoid-induced Angptl4 transcription. To unravel the by a series of physiological studies (2, 5 ). First, injecting www.jlr.org mechanism, we utilized small molecules to inhibit insulin ANGPTL4 recombinant proteins rapidly increases plasma signaling components and found that phosphatidylinositol TG and FFA levels ( 5, 6 ). Mice overexpressing Angptl4 in 3-kinase and Akt were vital for the suppression in H4IIE cells. muscle and adipose tissue have increased plasma TG levels at Univ of Calif Lib Biosciences Natural Res, on April 28, 2014 A forkhead box transcription factor response element ( FRE ) ( 7 ), and adenoviral-mediated overexpression of Angptl4 in was found near the 15 bp Angptl4 glucocorticoid response ele- liver causes hyperlipidemia and hepatic steatosis ( 8 ).
    [Show full text]
  • Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs
    pharmacy Article Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs Donatella Zodda 1,*, Rosario Giammona 2 and Silvia Schifilliti 2 1 Drug Department of Local Health Unit (ASP), Viale Giostra, 98168 Messina, Italy 2 Clinical Pharmacy Fellowship, University of Messina, Viale Annunziata, 98168 Messina, Italy; [email protected] (R.G.); silvia.schifi[email protected] (S.S.) * Correspondence: [email protected]; Tel.: +39-090-3653902 Received: 12 November 2017; Accepted: 11 January 2018; Published: 21 January 2018 Abstract: Prevention and treatment of dyslipidemia should be considered as an integral part of individual cardiovascular prevention interventions, which should be addressed primarily to those at higher risk who benefit most. To date, statins remain the first-choice therapy, as they have been shown to reduce the risk of major vascular events by lowering low-density lipoprotein cholesterol (LDL-C). However, due to adherence to statin therapy or statin resistance, many patients do not reach LDL-C target levels. Ezetimibe, fibrates, and nicotinic acid represent the second-choice drugs to be used in combination with statins if lipid targets cannot be reached. In addition, anti-PCSK9 drugs (evolocumab and alirocumab) provide an effective solution for patients with familial hypercholesterolemia (FH) and statin intolerance at very high cardiovascular risk. Recently, studies demonstrated the effects of two novel lipid-lowering agents (lomitapide and mipomersen) for the management of homozygous FH by decreasing LDL-C values and reducing cardiovascular events. However, the costs for these new therapies made the cost–effectiveness debate more complicated. Keywords: lipid lowering therapy; dyslipidemia; statins; fibrate; PCSK9 inhibitors; lomitapide 1.
    [Show full text]
  • NLA Task Force on Statin Safety - 2014 Update
    Journal of Clinical Lipidology (2014) 8, S1–S4 Executive Summary NLA Task Force on Statin Safety - 2014 update Terry A. Jacobson, MD, FNLA, Chair, The NLA Task Force on Statin Safety - 2014 Update* Department of Medicine, Office of Health Promotion and Disease Prevention, Emory University, 49 Jesse Hill Jr Drive SE, Atlanta, GA 30303, USA KEYWORDS: Statins; Statin drug; Statin muscle; Statin intolerance; Statin brain; Statin liver; Statin diabetes Statins are the most widely prescribed class of medications classified into these risk categories. Although shocking, in the United States and their benefits for lowering low- these numbers do not even account for the hundreds of mil- density lipoprotein cholesterol (LDL-C) and reducing the lions of patients who qualify for statins because they risk for coronary heart disease (CHD) are well docu- already have ASCVD, diabetes mellitus, or extremely mented.1 Statins have been the cornerstone of pharmaco- high LDL-C levels. Therefore, the potential risks and ben- therapy for the management of high blood cholesterol efits of statin use are a major US and worldwide public levels virtually since their development. The American health concern. Heart Association /American College of Cardiology 2013 In 2006, the National Lipid Association (NLA) guidelines recently expanded the number of individuals convened a Statin Safety Assessment Task Force of experts eligible for statin therapy by recommending it for those who published their findings on specific questions related to with: (1) clinical atherosclerotic
    [Show full text]
  • STATIN-FIBRATE REPORT: Focus on Safety VHA Pharmacy Benefits Management-Strategic Healthcare Group and the Medical Advisory Panel
    Statin-Fibrate Safety Report-Final STATIN-FIBRATE REPORT: Focus on Safety VHA Pharmacy Benefits Management-Strategic Healthcare Group and The Medical Advisory Panel Executive Summary: (Key Questions) Efficacy a. Is there evidence to demonstrate an advantage with regard to reducing coronary health outcomes in patients receiving a combination of statins plus fibrates compared to statins alone (e.g. especially in patients with TG in the 300 range-metabolic syndrome) to justify the risk of the combination? At this time, there is a lack of evidence to support a reduction in coronary health outcomes with the statin-fibrate combination. The LDS study would have helped answer this question but was stopped due to withdrawal of cerivastatin from the market. The ACCORD study will have in excess of 5000 patients with type 2 diabetes on the combination of fenofibrate plus simvastatin vs. simvastatin alone. The primary outcome measures in this trial will include nonfatal myocardial infarction and nonfatal stroke, cardiovascular death and overall mortality. However, data from ACCORD will not be available until 2008 or 2009. b. Which fibrates (e.g. fenofibrate or gemfibrozil) have evidence to support their benefit in reducing coronary heart disease health outcomes when used as monotherapy? To summarize, when evaluated in primary prevention (WHO study), clofibrate was associated with a reduction in the risk for nonfatal MI. However, an excess in total mortality was also observed in the clofibrate group compared to placebo. This increase was attributed to deaths from diseases of the liver, intestines and gallbladder. In secondary prevention (CDP study), clofibrate was not significantly different from placebo with regard to reducing coronary heart disease (CHD) events.
    [Show full text]